Open-Label Trial of MABp1, a True Human Monoclonal Antibody Targeting Interleukin 1α, for the Treatment of Psoriasis

JAMA Dermatol. 2015 May;151(5):555-6. doi: 10.1001/jamadermatol.2014.5391.

Authors

Kyle M Coleman¹, Johann E Gudjonsson², Michael Stecher³

Affiliations

¹ Westlake Dermatology and Cosmetic Surgery, Austin, Texas.
² Department of Dermatology, University of Michigan, Ann Arbor.
³ XBiotech USA, Austin, Texas.

PMID: 25715176
DOI: 10.1001/jamadermatol.2014.5391

No abstract available

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antibodies, Monoclonal / blood
Antibodies, Monoclonal / therapeutic use*
Drug Administration Schedule
Follow-Up Studies
Half-Life
Humans
Injections, Subcutaneous
Interleukin-1alpha / metabolism*
Psoriasis / drug therapy*
Psoriasis / metabolism*
Treatment Outcome

Substances

Antibodies, Monoclonal
Interleukin-1alpha
MABp1 monoclonal antibody